BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38782067)

  • 1. Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
    Liang Y; Xiao W; Peng Y; Zhang S; Dong J; Zhao J; Wang Y; Zhang M; Liu Z; Yu B
    Antiviral Res; 2024 Jul; 227():105917. PubMed ID: 38782067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.
    Sun YS; Zhou JJ; Zhu HP; Xu F; Zhao WB; Lu HJ; Wang Z; Chen SQ; Yao PP; Jiang JM; Zhou Z
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
    Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y
    Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916
    [No Abstract]   [Full Text] [Related]  

  • 6. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
    Ellis D; Brunette N; Crawford KHD; Walls AC; Pham MN; Chen C; Herpoldt KL; Fiala B; Murphy M; Pettie D; Kraft JC; Malone KD; Navarro MJ; Ogohara C; Kepl E; Ravichandran R; Sydeman C; Ahlrichs M; Johnson M; Blackstone A; Carter L; Starr TN; Greaney AJ; Lee KK; Veesler D; Bloom JD; King NP
    Front Immunol; 2021; 12():710263. PubMed ID: 34267764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Huang J; Wang W; Li H; Bai Y; Song Y; Jiao C; Jin H; Huang P; Zhang H; Xia X; Yan F; Li Y; Wang H
    Antiviral Res; 2024 Jul; 227():105905. PubMed ID: 38740191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
    Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
    Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
    Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
    Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    Sci Adv; 2021 Mar; 7(12):. PubMed ID: 33741598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
    Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
    Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
    Cohen AA; Gnanapragasam PNP; Lee YE; Hoffman PR; Ou S; Kakutani LM; Keeffe JR; Wu HJ; Howarth M; West AP; Barnes CO; Nussenzweig MC; Bjorkman PJ
    Science; 2021 Feb; 371(6530):735-741. PubMed ID: 33436524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.